Is PI-RADS Version 2.1 Outdated for Prostate MRI?
In a new point-counterpoint discussion published in the American Journal of Roentgenology, researchers debate the merits and limitations of the Prostate Imaging Reporting and Data System (PI-RADS) version 2.1.
Does the Prostate Imaging Reporting and Data System (PI-RADS) version 2.1 need an overhaul?
Debating the issue in a set of point-counterpoint articles, recently published in the American Journal of Roentgenology, researchers noted that a prevailing majority of technical specifications for the PI-RADS system haven’t changed in nearly 10 years, but the system reportedly offers a strong tool for ruling out clinically significant prostate cancer (csPCa).
Here are eight takeaways from the point-counterpoint discussion.
1. In the last decade, only 22 publications focusing on MRI have advocated for changes to the PI-RADS system and the researchers noted that only five of those publications provided metrics to support the impact of the proposed changes for the “whole spectrum of outcomes,” according to lead counterpoint author Leonardo Kayat Bittencourt, M.D., Ph.D, who is affiliated with the Department of Radiology at University Hospitals Cleveland Medical Center in Ohio, and colleagues.
2. Thirty of 35 parameters for PI-RADS technical specifications have not changed since the introduction of PI-RADS version 2 (v2) in 2015, according to the point author Tristan Barrett, MBBS, MD, who is affiliated with the Department of Radiology at the University of Cambridge and Cambridge University Hospitals NHS Foundation Trust Addenbrooke’s Hospital in Cambridge, United Kingdom.
Researchers debated the merits and drawbacks of the Prostate Imaging Reporting and Data System (PI-RADS) version 2.1 in recent point-counterpoint articles published in the American Journal of Roentgenology. (Images courtesy of Adobe Stock.)
3. Dr. Barrett noted that current Prostate Imaging Quality (PI-QUAL) recommendations suggest that meeting only seven of the aforementioned PI-RADS parameters facilitates optimal quality across T2-weighted, diffusion-weighted, and dynamic contrast-enhanced MRI sequences.
4. In contrast to a T2-weighted MRI-led approach recommended by the PI-RADS system, Dr. Barrett said recently published research points out that diffusion-weighted imaging MRI (DWI MRI) interpretation of the transition zone prior to T2WI MRI leads to a 36 percent improvement in specificity (90 percent) and a 16 percent increase in inter-reader agreement (73 percent).
5. Dr. Bittencourt and colleagues maintained that the current PI-RADS v2.1 system provides straightforward protocols and acquisition parameters that are “readily implementable” in 1.5 T or higher MRI scanners without the need for proprietary technology.
6. The current PI-RADS recommendations don’t reflect advances in signal-to-noise ratio (SNR) and spatial resolution driven by increased availability of synthetic b-value DWI MRI and the advent of deep learning reconstruction, according to Dr. Barrett.
7. Dr. Barrett noted that current PI-RADS recommendations do not provide guidance on the use of biparametric MRI (bpMRI).
8. Citing a 70-study meta-analysis published earlier this year, the Dr. Bittencourt and colleagues pointed out that the current PI-RADS system has a 93 percent sensitivity for excluding csPCa.
Multinational Study Reaffirms Value of Adjunctive AI for Prostate MRI
June 16th 2025The use of adjunctive AI in biparametric prostate MRI exams led to 3.3 percent and 3.4 percent increases in the AUC and specificity, respectively, for clinically significant prostate cancer (csPCa) in a 360-person cohort drawn from 53 facilities.
New PSMA PET Prep Product Now Available in the U.S.
June 11th 2025Offering an extended shelf life, the FDA-approved Gozellix, a preparation kit for gallium-68 (68Ga) gozetotide injection, is indicated for use in PSMA PET imaging of prostate cancer patients with suspected recurrence or metastasis.
Study: AI-Generated ADC Maps from MRI More Than Double Specificity in Prostate Cancer Detection
June 5th 2025Emerging research showed that AI-generated ADC mapping from MRI led to significant increases in accuracy, PPV and specificity in comparison to conventional ADC mapping while achieving a 93 percent sensitivity for PCa.
ASCO: Study Reveals Significant Racial/Ethnic Disparities with PSMA PET Use for Patients with mPCa
May 30th 2025Latinx patients with metastatic prostate cancer were 63 percent less likely than non-Hispanic White patients to have PSMA PET scans, according to a study of 550 patients presented at the American Society of Clinical Oncology (ASCO) conference.
What a New PSMA PET/CT Study Reveals About Local PCa Treatment and High-Risk Recurrence
May 16th 2025For patients at high-risk for biochemical recurrence of prostate cancer, PSMA PET/CT findings revealed that 77 percent had one or more prostate lesions after undergoing local radiation therapy or radical prostatectomy, according to a recent study.
